These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31522425)

  • 1. Immunophenotyping of Acute Lymphoblastic Leukemia.
    DiGiuseppe JA; Cardinali JL
    Methods Mol Biol; 2019; 2032():297-310. PubMed ID: 31522425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
    Digiuseppe JA
    Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
    Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic monitoring in adults with acute lymphoblastic leukemia.
    Vidriales MB; Orfao A; San-Miguel JF
    Curr Oncol Rep; 2003 Sep; 5(5):413-8. PubMed ID: 12895394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics and monitoring of minimal residual disease in patients with T acute lymphoid leukemia by flow cytometry with two 4-color combinations of fluorescent antibodies].
    Li L; Yuan XJ; Xu C; Jiang LM; Shen LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1103-9. PubMed ID: 23114128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
    DiGiuseppe JA; Tadmor MD; Pe'er D
    Cytometry B Clin Cytom; 2015; 88(5):294-304. PubMed ID: 25974871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric monitoring of residual disease in acute leukemia.
    Wood BL
    Methods Mol Biol; 2013; 999():123-36. PubMed ID: 23666694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow.
    Nowak R; Oelschlaegel U; Schuler U; Zengler H; Hofmann R; Ehninger G; Andreeff M
    Cytometry; 1997 Feb; 30(1):47-53. PubMed ID: 9056742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
    Weir EG; Cowan K; LeBeau P; Borowitz MJ
    Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotyping of leukemia.
    Campana D; Behm FG
    J Immunol Methods; 2000 Sep; 243(1-2):59-75. PubMed ID: 10986407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.